Vanderbilt to Study Ramipril
Researchers at Vanderbilt University, Nashville, Tenn., have launched a study of ramipril (Altace), an angiotensin-converting enzyme inhibitor, to see whether it will prevent or delay the onset of type 2 diabetes. “We have already found that it can return someone with prediabetes back to a normal blood glucose level, so the big question is how does this work?” Dr. Stephen Davis, lead investigator and chief of the division of diabetes, endocrinology, and metabolism at Vanderbilt, said in a statement. “The mechanisms of how [ramipril] affects blood glucose are not known. I think this is going to be the first study, and we hope a breakthrough study, that can provide this important information.” Study candidates include patients aged 20–65 years who are at risk for diabetes or have been told they have borderline diabetes or hypertension.
—From Staff Reports